69980-83-2

Usage

Uses

Used in Chemical Industry:
2-(2H-Benzo[d][1,2,3]triazol-2-yl)ethanamine is used as a stabilizer and corrosion inhibitor for enhancing the durability and performance of metals, plastics, and rubber in various industrial applications. Its ability to prevent degradation and corrosion contributes to the longevity and reliability of these materials.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 2-(2H-Benzo[d][1,2,3]triazol-2-yl)ethanamine is used as a building block in the synthesis of various pharmaceutical compounds. Its unique structure and properties make it a valuable component in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Synthesis:
Similarly, in the agrochemical sector, BTA-1 is utilized as a key component in the synthesis of agrochemicals, such as pesticides and herbicides. Its incorporation into these products helps improve their effectiveness and stability, contributing to more efficient and sustainable agricultural practices.
Used in Research and Development:
2-(2H-Benzo[d][1,2,3]triazol-2-yl)ethanamine is also employed in research and development activities, where its versatile properties and wide range of applications make it an essential tool for exploring new chemical reactions, syntheses, and potential applications in various industries.

Upstream product

• 939-72-0 2-(2-hydroxyethyl)-benzotriazole 
• 51126-65-9 potassium salt of benzotriazole 
• 69218-51-5 ethyl 2-(2H-benzo[d][1,2,3]triazol-2-yl)acetate 
• 273-02-9 2H-benzo[d][1,2,3]triazole 
• 74731-95-6 2-(N-phthalimidoethyl)-1,2,3-benzotriazole 

Relevant academic research and scientific papers

Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs

Phenylethylthiazolylthiourea (PETT) derivatives have been identified as a new series of nonnucleoside inhibitors of HIV-1 RT. Structure-activity relationship studies of this class of compounds resulted in the identification of N-[2-(2-pyridyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea hydrochloride (trovirdine; LY300046.HCl) as a highly potent anti-HIV-1 agent. Trovirdine is currently in phase one clinical trials for potential use in the treatment of AIDS. Extension of these structure-activity relationship studies to identify additional compounds in this series with improved properties is ongoing. A part of this work is described here. Replacement of the two aromatic moleties of the PETT compounds by various substituted or unsubstituted heteroaromatic rings was investigated. In addition, the effects of multiple substitution in the phenyl ring were also studied. The antiviral activities were determined on wild-type and constructed mutants of HIV-1 RT and on wild-type HIV-1 and mutant viruses derived thereof, Ile100 and Cys181, in cell culture assays. Some selected compounds were determined on double- mutant viruses, HIV-1 (Ile100/Asn103) and HIV-1 (Ile100/Cys181). A number of highly potent analogs were synthesized. These compounds displayed IC50's against wild-type RT between 0.6 and 5 nM. In cell culture, these agents inhibited wild-type HIV-1 with ED50's between I and 5 nM in MT-4 cells. In addition, these derivatives inhibited mutant HIV-1 RT (Ile 100) with IC50's between 20 and 50 nM and mutant HIV-1 RT (Cys 181) with IC50's between 4 and 10 nM, and in cell culture they inhibited mutant HIV-1 (Ile100) with ED50's between 9 and 100 nM and mutant HIV-1 (Cys181) with ED50's between 3 and 20 nM.